ESC Premium Access

Non-statin lipid-lowering therapy in coronary atherosclerosis regression: A meta-analysis and meta-regression.

Congress Presentation

About the speaker

Doctor Lorenzo Martin Lobo

Campo de Mayo Military Hospital, Buenos Aires (Argentina)
0 follower

7 more presentations in this session

Updated treatment thresholds in the 2019 ESC/EAS dyslipidaemia guidelines substantially expand indications for statin use for primary prevention at population level: results from the Rotterdam Study

Speaker: Ms J. Pavlovic (Rotterdam, NL)

Thumbnail

Does Evolocumab use in Europe match 2019 ESC/EAS lipid guidelines? Results from the HEYMANS study

Speaker: Professor K. Ray (London, GB)

Thumbnail

REDUCE-IT: total ischemic events reduced across the full range of baseline LDL cholesterol and other key subgroups

Speaker: Professor D. Bhatt (Boston, US)

Thumbnail

REDUCE-IT: accumulation of data across prespecified interim analyses to final results

Speaker: Professor B. Olshansky (Iowa City, US)

Thumbnail

Are the results of clinical trials relevant in the real world? The applicability of REDUCE-IT to the FAST-MI Registry.

Speaker: Professor J. Ferrieres (Toulouse, FR)

Thumbnail

Access the full session

Non-statin Treatment of Dyslipidemia

Speakers: Doctor L. Lobo, Ms J. Pavlovic, Professor K. Ray, Professor D. Bhatt, Professor B. Olshansky...
Thumbnail

About the event

Image

ESC CONGRESS 2020 - The Digital Experience

28 August - 1 September 2020

Sessions Presentations

Related content

Open Access

LDL-c in the management of high CV risk: Changing the paradigm for prevention.

27 August 2021

ESC Premium Access

Will coronary atherosclerosis be eliminated?

27 August 2021

ESC Premium Access

REDUCE-IT PRIOR MI: Reduction in Ischemic Events, Including Cardiovascular Mortality, with Icosapent Ethyl in Patients with Prior Myocardial Infarction

27 August 2021

ESC 365 is supported by

logo Novo Nordisk